Cargando…
Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
Indoximod has shaped our understanding of the biology of IDO1 in the control of immune responses, though its mechanism of action has been poorly understood. Previous studies demonstrated that indoximod creates a tryptophan (Trp) sufficiency signal that reactivates mTOR in the context of low Trp conc...
Autores principales: | Brincks, Erik L., Adams, James, Wang, Lifu, Turner, Benjamin, Marcinowicz, Agnieszka, Ke, Jiyuan, Essmann, Michael, Mautino, Lucía M., Allen, Clarissa Van, Kumar, Sanjeev, Vahanian, Nicholas, Link, Charles, Mautino, Mario R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321702/ https://www.ncbi.nlm.nih.gov/pubmed/32637034 http://dx.doi.org/10.18632/oncotarget.27646 |
Ejemplares similares
-
A phase I study of indoximod in patients with advanced malignancies
por: Soliman, Hatem H., et al.
Publicado: (2016) -
Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2020) -
Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2021) -
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
por: Zakharia, Yousef, et al.
Publicado: (2021) -
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
por: Metz, Richard, et al.
Publicado: (2012)